Effect of dalteparin, a low-molecular-weight heparin, as adjunctive therapy in patients with Kawasaki disease: a retrospective study

Table 4 Comparison between the 21st Nationwide survey and the second cohort

	21st Nationwide survey n; %	Second cohort group n; %	p-value	Odds ratio	95% CI
Total	23,730; 100.0	112; 100.0		(crude)
Initial IVIG therapy	21,247; 89.5	104; 92.9	0.24	0.46	0.23–0.95
			0.31*	1.20*	0.86–1.69*
Acute phase CAL	2,044; 8.6	3; 2.7	0.03	3.43	1.09–10.79
Cardiac sequelae	696; 2.9	1; 0.9	0.32	3.35	0.47–24.06
Additional IVIG therapy	4,049; 17.1	10; 8.9	0.02	2.10	1.10–4.02
Resistance for IVIG therapy	3,532; 14.9	4; 3.6	< 0.001	5.16	1.09–14.00

*Adjusted odds ratio for dosage of initial IVIG therapy in both groups was obtained using the Mantel-Haenstzel method adjusted for various initial dosages of intravenous immunoglobulin (2 g/kg, 1 g/kg, 400 mg/kg, or various dosages of IVIG). Adjusted odds ratio for acute-phase CAL, cardiac sequelae, and additional IVIG therapy were not analyzed because there were no descriptions of dosages of various initial IVIG in the nationwide surveys.

ISSN: 1471-2431